

SCRI Trials and Trial Regimen Updates

The following updates were completed between December 12, 2025, and January 20, 2026. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens.

For questions about these trials and regimens, please contact SCRiKMEMRedits@McKesson.com.

New Builds Completed

Study Number	Notes for New Build
25113	USOR 25113 BRE 474 Phase 3 Palazestrant or Placebo + Letrozole or Placebo + Ribociclib Q28D - v1.0 12Jun2025
25075	USOR 25075 GI 417 Phase 2 BMS-986504 or Placebo (400 mg) + Nab-paclitaxel + Gemcitabine Q28D - 24JUN2025 USOR 25075 GI 417 Phase 2 BMS-986504 or Placebo (600 mg) + Nab-paclitaxel + Gemcitabine Q28D - 24JUN2025
25030	USOR 25030 CLL 67 Phase 3 Arm A BGB-16673 Q28D - 13AUG2025 USOR 25030 CLL 67 Phase 3 Arm B Bendamustine + Rituximab Q28D - 13AUG2025 USOR 25030 CLL 67 Phase 3 Arm B Idelalisib + Rituximab Q28D - 13AUG2025 USOR 25030 CLL 67 Phase 3 Arm B Venetoclax + Rituximab Q28D - 13AUG2025 USOR 25030 CLL 67 Phase 3 Arm B Venetoclax Ramp-Up - 13AUG2025
24302	USOR 24302 GI 404 Phase 2 Arm A ONO-4578 + Opdivo + Bevacizumab + mFOLFOX6 Q28D - v3.0 20MAR2025 USOR 24302 GI 404 Phase 2 Arm B ONO-4578 + Opdivo + Bevacizumab + mFOLFOX6 Q28D - v3.0 20MAR2025 USOR 24302 GI 404 Phase 2 Arm C Bevacizumab + mFOLFOX6 Q28D - v3.0 20MAR2025
25007	USOR 25007 BRE 462 Phase 3 Arm 1 HER3-DXd Q84D - 25APR2025 USOR 25007 BRE 462 Phase 3 Arm 2 Capecitabine Q84D - 25APR2025 USOR 25007 BRE 462 Phase 3 Arm 2 Liposomal Doxorubicin Q84D - 25APR2025 USOR 25007 BRE 462 Phase 3 Arm 2 Nab-paclitaxel Q84D - 25APR2025 USOR 25007 BRE 462 Phase 3 Arm 2 Paclitaxel (80 mg/m ²) Q84D - 25APR2025 USOR 25007 BRE 462 Phase 3 Arm 2 Paclitaxel (90 mg/m ²) Q84D - 25APR2025 USOR 25007 BRE 462 Phase 3 Arm 2 T-DXd Q84D - 25APR2025
25131	USOR 25131 CML 30 Phase 3b Asciminib Q84D - v03 17MAY2024
24293	USOR 24293 GU 268 Phase 3 AAA817 + ARPI Q56D - v00 17JAN2025 USOR 24293 GU 268 Phase 3 AAA817 Q56D - v00 17JAN2025 USOR 24293 GU 268 Phase 3 ARPI Q56D - v00 17JAN2025 USOR 24293 GU 268 Phase 3 Cabazitaxel Q21D - v00 17JAN2025 USOR 24293 GU 268 Phase 3 Docetaxel Q21D - v00 17JAN2025

Study Number	Notes for New Build
LUN 537 (ILCC)	LUN 537 Phase 3 V940 or Placebo + Pembrolizumab Q42D - 14Aug2025
25004	USOR 25004 AML 81 Phase 3 Intensive Therapy Consolidation Ziftomenib or Placebo + Cytarabine Q28D - 15AUG2025 USOR 25004 AML 81 Phase 3 Intensive Therapy Induction Ziftomenib or Placebo + Cytarabine + Daunorubicin Q28D - 15AUG2025 USOR 25004 AML 81 Phase 3 Maintenance Ziftomenib or Placebo Q28D - 15AUG2025 USOR 25004 AML 81 Phase 3 Nonintensive Therapy Ziftomenib or Placebo + Venetoclax + Azacitidine Q28D - 15AUG2025
25114	USOR 25114 GYN 162 Phase 2 INCB123667 Q28D - v3 15AUG2025
24221	USOR 24221 CH 03 Phase 3 Mavorixafor (X4P-001) or Placebo Q52W
25009	USOR 25009 LYM 256 Phase 2 Bridging Therapy (Placeholder) - v6.0 11MAR2025 USOR 25009 LYM 256 Phase 2 Cyclophosphamide + Fludarabine D-5,-4,-3 - v6.0 11MAR2025 USOR 25009 LYM 256 Phase 2 LYL314 D0 - v6.0 11MAR2025
25110	USOR 25110 GYN 161 Phase 2 Substudy 1 Bevacizumab Q21D - v3.0 22AUG2025 USOR 25110 GYN 161 Phase 2 Substudy 1 Mirvetuximab soravtansine + Bevacizumab Q21D - v3.0 22AUG2025 USOR 25110 GYN 161 Phase 2 Substudy 2 Mirvetuximab soravtansine + Carboplatin Q21D - v3.0 22AUG2025
25086	USOR 25086 RM 1145 Phase 1b GSK5764227 Q21D - 05MAR2025
25021	USOR 25021 BRE 466 Phase 3 Arm A PF-07248144 + Fulvestrant Q28D - 07APR2025 USOR 25021 BRE 466 Phase 3 Arm B Everolimus + Exemestane Q28D - 07APR2025 USOR 25021 BRE 466 Phase 3 Arm B Everolimus + Fulvestrant Q28D - 07APR2025
25154	USOR 25154 GI 428 Phase 2 Pumitamig or Bevacizumab + FOLFIRI Q14D - 09Oct2025 USOR 25154 GI 428 Phase 2 Pumitamig or Bevacizumab + FOLFOX Q14D - 09Oct2025
25173	USOR 25173 LUN 650 Phase 2 PF-08634404 + Carboplatin + Etoposide Q21D fb PF-08634404 Q21D - 06Nov2025
25174	USOR 25174 LUN 651 Phase 1b Part A PF-08634404 + Sigvotatug Vedotin Q42D - 23Oct2025 USOR 25174 LUN 651 Phase 1b Part B PF-08634404 + PF-08046054 Q21D - 23Oct2025
25139	USOR 25139 BRE 475 Phase 3 Part 1 Cohort 1 LY4064809 + Palbociclib + ET Q28D - 08Sep2025

Study Number	Notes for New Build
25156	USOR 25156 LUN 645 Phase 3 Part 1 PF-08634404 or Placebo + Pembrolizumab or Placebo + Nab-paclitaxel + Carboplatin Q21D fb PF-08634404 or Placebo + Pembrolizumab or Placebo Q21D - 05Nov2025 USOR 25156 LUN 645 Phase 3 Part 1 PF-08634404 or Placebo + Pembrolizumab or Placebo + Paclitaxel + Carboplatin Q21D fb PF-08634404 or Placebo + Pembrolizumab or Placebo Q21D - 05Nov2025 USOR 25156 LUN 645 Phase 3 Part 2 PF-08634404 or Placebo + Pembrolizumab or Placebo + Pemetrexed + Carboplatin Q21D fb PF-08634404 or Placebo + Pembrolizumab or Placebo + Pemetrexed Q21D - 05Nov2025
24031	USOR 24031 GU 251 Phase 3 AAA817 Q56D - 18JUN2025 USOR 24031 GU 251 Phase 3 Standard of Care (Placeholder) - 18JUN2025
24325	USOR 24325 BRE 465 Phase 2 Arm A (1 or 2) Izalontamab Brengitecan Q21D - 30APR2025 USOR 24325 BRE 465 Phase 2 Arm B Capecitabine Q21D - 30APR2025 USOR 24325 BRE 465 Phase 2 Arm B Gemcitabine + Carboplatin Q21D - 30APR2025 USOR 24325 BRE 465 Phase 2 Arm B Nab-Paclitaxel Q28D - 30APR2025 USOR 24325 BRE 465 Phase 2 Arm B Paclitaxel Q28D - 30APR2025
24289	USOR 24289 LUN 589 Phase 3 Olomorasib or Placebo Q28D - 27JUN2025 USOR 24289 LUN 589 Phase 3 Part A Olomorasib or Placebo + Pembrolizumab Q21D - 27JUN2025 USOR 24289 LUN 589 Phase 3 Part B Olomorasib or Placebo + Durvalumab Q28D - 27JUN2025
24110	USOR 24110 LUN 605 Phase 2 Adjuvant Pembrolizumab Q21D - 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 1 Neoadjuvant Pembrolizumab + Gemcitabine + Carboplatin Q21D - 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 1 Neoadjuvant Pembrolizumab + Gemcitabine + Cisplatin Q21D - 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 1 Neoadjuvant Pembrolizumab + Paclitaxel + Carboplatin Q21D - 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 1 Neoadjuvant Pembrolizumab + Paclitaxel + Cisplatin Q21D - 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 1 Neoadjuvant Pembrolizumab + Pemetrexed + Carboplatin Q21D - 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 1 Neoadjuvant Pembrolizumab + Pemetrexed + Cisplatin Q21D - 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 2 Adjuvant Gemcitabine + Carboplatin Q21D - 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 2 Adjuvant Gemcitabine + Cisplatin Q21D - 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 2 Adjuvant Paclitaxel + Carboplatin Q21D - 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 2 Adjuvant Pemetrexed + Carboplatin Q21D - 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 2 Adjuvant Pemetrexed + Cisplatin Q21D - 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 2 Neoadjuvant sac-TMT + Pembrolizumab Q21D - 03JUL2025
25070	USOR 25070 LUN 535 Phase 1b BBO-8520 + Pembrolizumab Q21D - v5.0 03SEP2025 USOR 25070 LUN 535 Phase 1b BBO-8520 Q21D - v5.0 03SEP2025

Study Number	Notes for New Build
24270	USOR 24270 MDS 36 Phase 3 Azacitidine Q28D - v2.0 19SEP2024 USOR 24270 MDS 36 Phase 3 Ivosidenib Q28D - v2.0 19SEP2024
25116	USOR 25116 HN 43 Phase 3 Arm A Pembrolizumab + Carboplatin + Amivantamab Q21D - 23Jul2025 USOR 25116 HN 43 Phase 3 Arm B Pembrolizumab + Carboplatin + Fluorouracil Q21D - 23Jul2025 USOR 25116 HN 43 Phase 3 Arm B Pembrolizumab + Cisplatin + Fluorouracil Q21D - 23Jul2025

Updated Reference Information

Study Number	Updated Reference Information	Updated Drug Service Order Information	Updated Regimen Instructions	Other Changes
23094	PA10: 11 Apr 2025 (sponsor decision to hold pa9)	N/A	Regimen comments; Admin	Update drug; instructions
23095	PAv5.0: 30 Jul 2025	N/A	N/A	Update drug; instructions
24093	Memo: 03 Oct 25	N/A	N/A	Update drug; instructions
24094	Site Edits: IPC Dispensation update	N/A	N/A	Update drug; frequency
24234	PA 3.0; 04 August 2025	N/A	N/A	Update drug; instructions
22201	Update Drug Form to AIBW	N/A	N/A	Update drug; dose/form
24310	Memo; 08 Sept 2025	N/A	N/A	Update drug; dose/form
24267	PM v5.0; 10th December 2025	N/A	N/A	Update drug; instructions, name
23284	PA 3.0, 18 June 2025	N/A	Regimen comments; prophylaxis, observation	Update drug; procurement
23289	Version 3.3; 5th August 2025	N/A	N/A	Update drug; instructions

Study Number	Updated Reference Information	Updated Drug Service Order Information	Updated Regimen Instructions	Other Changes
24149	Version 4.0; 08 Sept 2025; V3.0;29Jul2025	N/A	Regimen comments; admin, premedication	Update drug; instructions
25018	Version 4.1; 24th November 2025	N/A	N/A	Update drug; instructions
24043	PA v3.0; 29 July 2025	N/A	Regimen comments; Admin	Update drug; premedication
24196	Version 3.0; 26 March 2025	N/A	Regimen comments; admin, prophylaxis, premedication	N/A
24070	Version 2.0; 05 November 2025 - PM v3.0; 06NOV2025	N/A	Regimen comments; Observation	Update drug; dose/form, instruction
24070	DIL; 21 November 2025	N/A	N/A	Update drug; instructions
24070	Memo; 18 November 2025	N/A	N/A	Update drug; instructions
24144	PM v8.0: 15 Oct 2025	N/A	N/A	Update drug; name and instructions
24006	PM v2.1: 09 Dec 2025	N/A	N/A	Update drug; instructions and name
23107	Version 5.0; 16 July 2025	N/A	Regimen comments; admin	Update drug; instructions
21270	PA v9.0: 03 Nov 2025	N/A	Regimen comments; premedication	Update drug; instructions
23234	PA v3.0; 13 May 2025	N/A	Regimen comments; admin, premedication	Update drug; admin/prep, instructions

Study Number	Updated Reference Information	Updated Drug Service Order Information	Updated Regimen Instructions	Other Changes
23240	Version 8.0; 17 Sept 2025	N/A	Regimen comments; admin	Update drug; instructions
23085	PA v4.0; 20 June 2025	N/A	N/A	Update drug; instructions. Added drug.